Treatment of wet age-related macular degeneration: Now and future

Authors:  Ding Xiaoyan,  Wang Zhirong,  Sun Limei

DOI: 10.3760/cma.j.issn.2095-0160.2019.01.014
Published 2019-01-10
Cite as Chin J Exp Ophthalmol, 2019,37(1): 63-68.

Abstract                              [Download PDF] [Read Full Text]

Wet age-related macular degeneration (AMD), which is the leading cause of visual impairment in elderly people, significantly affects quality of life of millions worldwide.Currently, anti-VEGF is the first-line therapy for wAMD, bringing encouraging results in improving the vision.However, not all of the patients will response to this therapy, moreover, anti-VEGF may be associated with several issues, such as multiple injections, systemic adverse effects, delay or lack of response.With a deep understanding of the mechanism of wAMD, there are rapid developments of new approaches to more effective therapy.Ophthalmologists should pay attention to the advantages and disadvantages of these anti-VEGF drugs as well as the current advances of anti-VEGF drugs in order to provide better treating strategies for wAMD patients better.

Key words:

Age-related macular degeneration; Vascular endothelial growth factor; Monoclone antibody; Tusion-protein

Contributor Information

Ding Xiaoyan
Zhongshan Ophthalmic Centere, State Key Laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou 510060, China
Wang Zhirong
Sun Limei
(Read 61 times, 1 visits today)
Updated: January 16, 2023 — 2:14 am